A new pancreatic cancer drug daraxonrasib DOUBLES overall survival time in a large phase 3 trial.
What is particularly impressive is that all these patients had already failed the standard-of-care first line therapy.
This drug is likely to get fast track approval by the FDA.
Full details:
cnb.cx/4tGgbDP
Quoted:
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

